Double -Blind Randomized Multicenter Controlled Clinical Trial of Recombinant Interferon Α- 2a Gel Versus Placebo in Prevention of Condyloma Acuminata Relapse

WANG Ke,HAN Gang-wen,ZHENG He-yi,LI Fu -qiu,BAI Yi-jie,XU Jin-hua,ZHU Xue-jun
DOI: https://doi.org/10.3969/j.issn.1001-6821.2006.02.008
2006-01-01
Abstract:Objective To study the efficacy and safety of recombinant interferon α-2a gel in prevention of condyloma acuminata relapse. Methods Recombinant interferon α-2a gel or placebo was applied 4 times daily for 8 weeks after condyloma acuminata was clinically cleared by laser、cryotheropy or electrodesiccation,both treatment groups were followed up for 12 weeks.Results One hundred and fifty four cases were involved. The results showed that relapse rates of recombinant interferon α-2a gel were lower than that of placebo at week 2,4,8,12,16,20. The relapse rates between two groups had significant statistic differences. Conclusion Recombinant interferon α-2a gel is a topical drug with good efficacy,safety and tolerability in prevention of condyloma acuminata relapse.
What problem does this paper attempt to address?